Vaccine Value Profile for Schistosomiasis

The GW VRU Director, Dr. David Diemert, co-authored an article assessing the value of public health, economic, and societal value of developing a vaccine to prevent and reduce the transmission of Schistosomiasis. Endemic in 78 countries, it is estimated that approximately 236 million people were treated for Schistosomiasis in 2019. This article evaluates the global public health need for a vaccine.

Latest News

FDA Approves Abrysvo for Adults 18-59 at Increased Risk for RSV
Mpox Vaccine Is Safe and Generates a Robust Antibody Response in Adolescents
Latest news about the results of the COVAIL trial regarding the Sanofi booster. GW participated as one of the many sites for this COVID-19 vaccine study.